Specialty: Dementias and neurodegeneration, Primary sub-specialty: Parkinson's Disease
Conditions
Interventions
Participants will be randomised in 1:1 (stratified by sex) to one of two groups.
Control group: Participants attend a single 30 minute appointment to receive standard conservative adv
Sponsors
Newcastle upon Tyne Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Idiopathic Parkinson's disease 2. Urinary symptoms defined as one or more of the following: 2.1. Urinary frequency (need to pass urine 7 or more times during the day) 2.2. Urgency: A sudden compelling desire to pass urine which is difficult to defer accessed 2.3. Urge incontinence : involuntary leakage of urine accompanied by/ or immediately preceded by urgency 2.4. Mixed urinary incontinence: involuntary leakage associated with urgency and also with exertion, effort, sneezing or coughing. Where clinically urge incontinence is the major component 2.5. Over active bladder: urgency combined with frequency or nocturia (need to pass urine one or more times a night)
Exclusion criteria
Exclusion criteria: 1. Dementia such that they cannot follow training program or a Montreal Cognitive Assessment Score 200ml on post void bladder scan 12. Previous Urogynecological Surgery for incontinence 12. Poorly controlled diabetes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Number of urgency episodes on 3 day bladder diary from baseline to 12 weeks 2. Global measure of improvement (much improved, a little improved, no change, worse much worse) is measured by visual analogue scale at 12 weeks All primary and secondary measures will be repeated 20 week to see if improvements are sustained once the intervention is completed. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Patient perception of bladder control is measured using baseline at 12 weeks 2. Number of incontinence episodes is measured using bladder diary baseline at 12 weeks 3. Number of micturition during day is measured using bladder diary baseline at 12 weeks 4. Number of nocturnal voids is measured using bladder diary baseline at 12 weeks 5. Average volume voided per micturition is measured using bladder diary baseline at 12 weeks 6. Maximum postural drop on standing is measured using bladder diary baseline at 12 weeks 7. bladder symptoms are measured using the ICIQ-OAB score at baseline and 12 weeks 8. Patient quality of life is measured using the ICIQ-OAB_QOL and PDQ 39 questionnaires at baseline and 12 weeks 9. Patient satisfaction with bladder control is measured using a visual analogue scale (VAS) at … 10. Non-motor symptom score is measured using PDUKNon-motor symptom score at baseline and 12 weeks 11. Carer quality of life is measured using the OAB-fim and PDQ carer questionnaire at baseline and 12 weeks All primary and secondary measures will be repeated 20 week to see if improvements are sustained once the intervention is completed. | — |
Countries
United Kingdom
Outcome results
None listed